Ospemifene and vulvovaginal atrophy: an update of the clinical profile for post-menopausal women.
Costantino Di CarloAngelo CagnacciFilippo MurinaSilvia MaffeiAngelamaria BecorpiStefano LelloPublished in: Expert opinion on pharmacotherapy (2024)
Of the 157 retrieved records, 25 primary studies met the inclusion criteria (15 regarding efficacy and safety, two for additional effects, and four for adherence and satisfaction with the OSP treatment). Seven RCTs involved nearly 5,000 patients, 10/18 prospective observational studies 563, and six retrospective analyses 356,439.Evidence of OSP treatment in PMW with GSM relies on RCTs and remarkable real-world data. The studies showcased the high clinical response to symptoms, the favorable safety profile of OSP with very few adverse events, a neutral impact on the endometrium, breast, bone, and thrombosis, and the possible improvement of cardiovascular risk factors.
Keyphrases
- cardiovascular risk factors
- end stage renal disease
- ejection fraction
- cardiovascular disease
- newly diagnosed
- metabolic syndrome
- peritoneal dialysis
- prognostic factors
- pulmonary embolism
- case control
- machine learning
- pregnant women
- physical activity
- adipose tissue
- skeletal muscle
- electronic health record
- weight loss
- depressive symptoms